Frédéric Vanhoutte

1.3k total citations
35 papers, 983 citations indexed

About

Frédéric Vanhoutte is a scholar working on Rheumatology, Molecular Biology and Genetics. According to data from OpenAlex, Frédéric Vanhoutte has authored 35 papers receiving a total of 983 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Rheumatology, 9 papers in Molecular Biology and 9 papers in Genetics. Recurrent topics in Frédéric Vanhoutte's work include Chronic Lymphocytic Leukemia Research (9 papers), Rheumatoid Arthritis Research and Therapies (8 papers) and Cytokine Signaling Pathways and Interactions (4 papers). Frédéric Vanhoutte is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Rheumatoid Arthritis Research and Therapies (8 papers) and Cytokine Signaling Pathways and Interactions (4 papers). Frédéric Vanhoutte collaborates with scholars based in Belgium, United States and Ukraine. Frédéric Vanhoutte's co-authors include Annegret Van der Aa, Maria Greenwald, Pille Harrison, Chantal Tasset, Minodora Mazur, Mykola Stanislavchuk, Florence Namour, René Westhovens, Peter C. Taylor and Rieke Alten and has published in prestigious journals such as Gastroenterology, Cancer Research and Clinical Infectious Diseases.

In The Last Decade

Frédéric Vanhoutte

34 papers receiving 966 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Frédéric Vanhoutte Belgium 15 390 242 235 219 186 35 983
Debra M. Meyer United States 11 464 1.2× 393 1.6× 195 0.8× 411 1.9× 221 1.2× 13 1.2k
René Galien Belgium 8 290 0.7× 308 1.3× 123 0.5× 159 0.7× 133 0.7× 32 706
Michael I. Jesson United States 13 502 1.3× 666 2.8× 274 1.2× 467 2.1× 255 1.4× 21 1.6k
Lichen Teng China 17 371 1.0× 109 0.5× 270 1.1× 299 1.4× 228 1.2× 63 1.0k
P. Brent Ferrell United States 17 110 0.3× 264 1.1× 325 1.4× 341 1.6× 296 1.6× 49 1.1k
Naresh Punwani United States 12 230 0.6× 241 1.0× 178 0.8× 224 1.0× 268 1.4× 17 803
Kourosh Lotfi Sweden 18 71 0.2× 264 1.1× 400 1.7× 108 0.5× 383 2.1× 54 968
Cynthia Kuk Canada 21 117 0.3× 306 1.3× 256 1.1× 69 0.3× 36 0.2× 42 1.5k
Antonella Gozzini Italy 22 234 0.6× 408 1.7× 752 3.2× 147 0.7× 1.0k 5.6× 75 1.7k
Sara Redaelli Italy 19 205 0.5× 260 1.1× 463 2.0× 58 0.3× 505 2.7× 41 1.2k

Countries citing papers authored by Frédéric Vanhoutte

Since Specialization
Citations

This map shows the geographic impact of Frédéric Vanhoutte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédéric Vanhoutte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédéric Vanhoutte more than expected).

Fields of papers citing papers by Frédéric Vanhoutte

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédéric Vanhoutte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédéric Vanhoutte. The network helps show where Frédéric Vanhoutte may publish in the future.

Co-authorship network of co-authors of Frédéric Vanhoutte

This figure shows the co-authorship network connecting the top 25 collaborators of Frédéric Vanhoutte. A scholar is included among the top collaborators of Frédéric Vanhoutte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frédéric Vanhoutte. Frédéric Vanhoutte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Carstens, Russ P., Yash Kapoor, Jean‐François Denef, et al.. (2025). Safety and Pharmacokinetics of MK ‐8527 in Adults Without HIV. Clinical and Translational Science. 18(9). e70331–e70331.
2.
3.
Vanhoutte, Frédéric, Wen Liu, Richard T. Wiedmann, et al.. (2022). Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial. EBioMedicine. 75. 103811–103811. 18 indexed citations
4.
Vanhoutte, Frédéric, Liang Su, Marcella Ruddy, et al.. (2020). Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti‐Activin A): Results From a First‐in‐Human Phase 1 Study. The Journal of Clinical Pharmacology. 60(11). 1424–1431. 36 indexed citations
5.
Frydman‐Marom, Anat, et al.. (2019). Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX‐02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers. Clinical Pharmacology in Drug Development. 8(8). 984–994. 58 indexed citations
6.
Berliba, Elina, Frédéric Vanhoutte, Steven S. Good, et al.. (2019). Safety, Pharmacokinetics, and Antiviral Activity of AT-527, a Novel Purine Nucleotide Prodrug, in Hepatitis C Virus-Infected Subjects with or without Cirrhosis. Antimicrobial Agents and Chemotherapy. 63(12). 25 indexed citations
7.
Aar, Ellen M. van der, Julie Desrivot, David Amantini, et al.. (2018). ADAMTS-5 inhibitor GLPG1972, a potential new treatment in osteoarthritis, shows favorable safety, pharmacokinetics and pharmacodynamics in healthy subjects. Osteoarthritis and Cartilage. 26. S310–S310. 9 indexed citations
8.
Kavanaugh, Arthur, Joel M. Kremer, Regina Cseuz, et al.. (2016). Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Annals of the Rheumatic Diseases. 76(6). 1009–1019. 176 indexed citations
9.
Cirkel, Geert A., Bojana Milojkovic Kerklaan, Frédéric Vanhoutte, et al.. (2016). A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies. Investigational New Drugs. 34(2). 184–192. 53 indexed citations
10.
Namour, Florence, et al.. (2016). Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects. British Journal of Clinical Pharmacology. 82(1). 139–148. 47 indexed citations
11.
Kavanaugh, Arthur, Regina Cseuz, O. V. Reshetko, et al.. (2016). THU0173 Filgotinib (GLPG0634), An Oral Jak1 Selective Inhibitor Is Effective as Monotherapy in Patients with Active Rheumatoid Arthritis: Results from A 24-Week Phase 2B Dose Ranging Study. Annals of the Rheumatic Diseases. 75. 247–247. 11 indexed citations
12.
13.
Vanhoutte, Frédéric, Sonia Dupont, Roland Blanqué, et al.. (2015). P612. Human safety, pharmacokinetics and pharmacodynamics of the GPR84 antagonist GLPG1205, a potential new approach to treat IBD.. Journal of Crohn s and Colitis. 9(suppl 1). S387–S387. 3 indexed citations
14.
Vanhoutte, Frédéric, Annegret Van der Aa, Luc Meuleners, & Gerben van ‘t Klooster. (2013). THU0229 Safety and Efficacy of GLPG0634, a Selective JAK1 Inhibitor in Patients with Rheumatoid Arthritis: Results of a 4-Week Phase II a Dose Ranging, Multi-Center Trial. Annals of the Rheumatic Diseases. 72. A242–A242. 1 indexed citations
15.
Westhovens, René, Filip De Keyser, Е. Л. Насонов, et al.. (2012). Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial. Annals of the Rheumatic Diseases. 72(5). 741–744. 18 indexed citations
16.
17.
Westhovens, René, Filip De Keyser, Е. Л. Насонов, et al.. (2011). A twelve-week exploratory phase II trial of GLPG0259 versus placebo in patients with active rheumatoid arthritis and inadequate response to methotrexate. Ghent University Academic Bibliography (Ghent University). 1 indexed citations
18.
Lorenzon, Giocondo, Lien Gheyle, Eva Vets, et al.. (2010). Abstract 1568: GLPG0187, a small molecule integrin antagonist, shows good safety and decrease in CTX levels in single ascending dose study. Cancer Research. 70(8_Supplement). 1568–1568. 3 indexed citations
19.
Radziszewski, Piotr, et al.. (2008). The centrally acting ion channel modulator flupirtine improves bladder function in animal models and patients with overactive bladder syndrome. 4 indexed citations
20.
Vanhoutte, Frédéric, et al.. (2007). Oral liarozole vs. acitretin in the treatment of ichthyosis: a phase II/III multicentre, double-blind, randomized, active-controlled study. British Journal of Dermatology. 156(5). 965–973. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Debra M. Meyer Breakdown of academic impact, for papers by René Galien Breakdown of academic impact, for papers by Michael I. Jesson Breakdown of academic impact, for papers by Lichen Teng Breakdown of academic impact, for papers by P. Brent Ferrell Breakdown of academic impact, for papers by Naresh Punwani Breakdown of academic impact, for papers by Kourosh Lotfi Breakdown of academic impact, for papers by Cynthia Kuk Breakdown of academic impact, for papers by Antonella Gozzini Breakdown of academic impact, for papers by Sara Redaelli
Rankless by CCL
2026